

Medical therapy cost considerations for glaucoma

American Journal of Ophthalmology

136, 18-25

DOI: [10.1016/s0002-9394\(03\)00102-8](https://doi.org/10.1016/s0002-9394(03)00102-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Medical Therapy Cost Considerations for Glaucoma. Evidence-Based Eye Care, 2003, 4, 214-215.	0.2	0
2	Need for Greater Scrutiny of Days Supply Values in DACON Calculations. Journal of Managed Care Pharmacy, 2004, 10, 172-173.	2.2	9
3	Using an infection-reporting database to improve outcomes in cataract-surgery patients. American Journal of Health-System Pharmacy, 2004, 61, 198-201.	1.0	2
4	Community Pharmacists Do Not Intentionally Transmit Incorrect Claim Information - But Caution Is Warranted in Days Supply Calculations. Journal of Managed Care Pharmacy, 2004, 10, 174-175.	2.2	0
6	Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size. American Journal of Ophthalmology, 2004, 137, S17-S23.	3.3	22
8	Current management of glaucoma. Current Opinion in Ophthalmology, 2004, 15, 119-126.	2.9	117
9	Letter to the Editor: Patient Persistency with Glaucoma Therapy. Journal of Ocular Pharmacology and Therapeutics, 2005, 21, 349-352.	1.4	1
10	Feasibility and Efficacy of a Mass Switch from Latanoprost to Bimatoprost in Glaucoma Patients in a Prepaid Health Maintenance Organization. Ophthalmology, 2005, 112, 2123-2130.	5.2	40
11	Efficacy and Safety of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Once Daily for Open-Angle Glaucoma or Ocular Hypertension. American Journal of Ophthalmology, 2005, 140, 242.e1-242.e11.	3.3	87
12	The Economic Burden of Glaucoma and Ocular Hypertension. Drugs and Aging, 2005, 22, 315-321.	2.7	67
13	Bimatoprost. Pharmacoeconomics, 2006, 24, 297-314.	3.3	13
14	Prostaglandin Analogues for the Treatment of Glaucoma and Ocular Hypertension. Pharmacoeconomics, 2006, 24, 743-750.	3.3	8
15	Projected cost comparison of selective laser trabeculoplasty versus glaucoma medication in the Ontario Health Insurance Plan. Canadian Journal of Ophthalmology, 2006, 41, 449-456.	0.7	81
16	Cost-Effectiveness of Monotherapy Treatment of Glaucoma and Ocular Hypertension With the Lipid Class of Medications. American Journal of Ophthalmology, 2006, 141, 15-21.	3.3	32
17	Medicare Prescription Drug Cards. JAMA Ophthalmology, 2006, 124, 1175.	2.4	1
18	The Economic Burden of Major Adult Visual Disorders in the United States. JAMA Ophthalmology, 2006, 124, 1754.	2.4	514
19	Effect of Proview self-tonometry on pharmaceutical compliance. Australasian journal of optometry, The, 2006, 89, 381-385.	1.3	7
20	Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clinical and Experimental Ophthalmology, 2006, 34, 755-764.	2.6	57

#	ARTICLE	IF	CITATIONS
21	Selecting between gatifloxacin and moxifloxacin drops in ambulatory ophthalmic surgery. American Journal of Health-System Pharmacy, 2006, 63, 1637-1640.	1.0	2
22	Efficiency of Instillation Methods for Prostaglandin Medications. Journal of Ocular Pharmacology and Therapeutics, 2006, 22, 477-482.	1.4	15
23	Bimatoprost for glaucoma therapy: pharmacology, clinical efficacy and controversy. Expert Review of Ophthalmology, 2006, 1, 141-158.	0.6	1
24	Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. British Journal of Ophthalmology, 2007, 91, 62-68.	3.9	32
25	Glaucoma in the United States and Europe. Journal of Glaucoma, 2007, 16, 471-478.	1.6	42
26	Daily Cost of Glaucoma Medications in China. Journal of Glaucoma, 2007, 16, 594-597.	1.6	12
27	Pharmacoeconomics of New Medications for Common Chronic Ophthalmic Diseases. Survey of Ophthalmology, 2007, 52, 618-633.	4.0	8
28	A Gap Analysis Approach to Assess Patient Persistence with Glaucoma Medication. American Journal of Ophthalmology, 2007, 144, 520-524.	3.3	25
29	Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management:a United States perspective. Current Medical Research and Opinion, 2007, 23, 2867-2875.	1.9	11
30	The Economic Implications of Glaucoma. Pharmacoeconomics, 2007, 25, 287-308.	3.3	59
31	Glaucoma surgery: toward a new global vision. Expert Review of Ophthalmology, 2007, 2, 149-153.	0.6	1
32	Evaluation of the Xal-Ease®, a latanoprost delivery system. Optometry - Journal of the American Optometric Association, 2007, 78, 30-33.	0.6	9
33	Using Pharmacy Claims Data to Study Adherence to Glaucoma Medications: Methodology and Findings of the Glaucoma Adherence and Persistency Study (GAPS). , 2007, 48, 5052.		238
34	Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension. BMC Ophthalmology, 2007, 7, 16.	1.4	15
35	Role of early trabeculectomy in primary open-angle glaucoma in the developing world. Eye, 2007, 21, 40-45.	2.1	19
36	A critical review of the full economic evaluations of pharmacological treatments for glaucoma. Journal of Medical Economics, 2008, 11, 719-741.	2.1	2
37	Cost Analysis of Glaucoma Medications. American Journal of Ophthalmology, 2008, 145, 106-113.	3.3	84
38	Health Care Charges for Patients with Ocular Hypertension or Primary Open-angle Glaucoma. Ophthalmology, 2008, 115, 633-638.e4.	5.2	14

#	ARTICLE	IF	CITATIONS
39	Doctorâ€™Patient Communication, Health-Related Beliefs, and Adherence in Glaucoma. <i>Ophthalmology</i> , 2008, 115, 1320-1327.e3.	5.2	251
40	Intraocular Pressure-Lowering Efficacy of Brinzolamide 1%/Timolol 0.5% Fixed Combination Compared with Brinzolamide 1% and Timolol 0.5%. <i>Ophthalmology</i> , 2008, 115, 1728-1734.e2.	5.2	45
41	Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis. <i>Canadian Journal of Ophthalmology</i> , 2008, 43, 33-41.	0.7	15
42	Pharmacogenetics of ophthalmic topical Î²-blockers. <i>Personalized Medicine</i> , 2008, 5, 377-385.	1.5	9
43	Medical Management of Glaucoma. <i>International Ophthalmology Clinics</i> , 2008, 48, 115-141.	0.7	11
44	Estimating the Rate of Progressive Visual Field Damage in Those with Open-Angle Glaucoma, from Cross-Sectional Data. , 2008, 49, 66.		115
45	Pharmacotherapy of the Ophthalmic Patient. , 2008, , 3-15.		3
47	First-year treatment costs among new initiators of topical prostaglandin analogs. <i>Clinical Ophthalmology</i> , 2009, 3, 637.	1.8	10
48	Considerations in glaucoma therapy: fixed combinations versus their component medications. <i>Clinical Ophthalmology</i> , 0, , 1.	1.8	49
49	Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden. <i>Clinical Ophthalmology</i> , 2009, 3, 471.	1.8	1
50	First-year treatment patterns among new initiators of topical prostaglandin analogs. <i>Current Medical Research and Opinion</i> , 2009, 25, 851-858.	1.9	21
51	Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model. <i>Eye</i> , 2009, 23, 132-140.	2.1	26
52	Determinants of Adherence to Glaucoma Medical Therapy in a Long-term Patient Population. <i>Journal of Glaucoma</i> , 2009, 18, 238-243.	1.6	113
53	Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy. <i>BMC Ophthalmology</i> , 2010, 10, 5.	1.4	18
54	First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008. <i>Current Medical Research and Opinion</i> , 2010, 26, 2769-2777.	1.9	6
55	The Role of Benzalkonium Chloride in the Occurrence of Punctate Keratitis: A Meta-Analysis of Randomized, Controlled Clinical Trials. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1914-1921.	1.9	20
56	The Lifetime Economic Burden of Keratoconus: A Decision Analysis Using a Markov Model. <i>American Journal of Ophthalmology</i> , 2011, 151, 768-773.e2.	3.3	64
57	Update on the role of alpha-agonists in glaucoma management. <i>Experimental Eye Research</i> , 2011, 93, 271-283.	2.6	65

#	ARTICLE	IF	CITATIONS
58	Drops, Drops, and More Drops. , 0, , .		2
59	Economic impact of primary open-angle glaucoma in Australia. <i>Clinical and Experimental Ophthalmology</i> , 2011, 39, 623-632.	2.6	71
60	Protocol for a randomised controlled trial to estimate the effects and costs of a patient centred educational intervention in glaucoma management. <i>BMC Ophthalmology</i> , 2012, 12, 57.	1.4	7
61	Longitudinal Trends in Resource Use in an Incident Cohort of Open-Angle Glaucoma Patients: Resource Use in Open-Angle Glaucoma. <i>American Journal of Ophthalmology</i> , 2012, 154, 452-459.e2.	3.3	23
62	Glaucoma: Present Challenges and Future Trends. <i>Ophthalmic Research</i> , 2013, 50, 197-208.	1.9	53
63	Direct healthcare costs of glaucoma treatment. <i>British Journal of Ophthalmology</i> , 2013, 97, 720-724.	3.9	21
64	A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension. <i>Indian Journal of Ophthalmology</i> , 2014, 62, 1136.	1.1	3
65	Projected Cost Comparison of Trabectome, iStent, and Endoscopic Cyclophotocoagulation Versus Glaucoma Medication in the Ontario Health Insurance Plan. <i>Journal of Glaucoma</i> , 2014, 23, e112-e118.	1.6	101
66	Economic Analysis of the Ex-PRESS Miniature Glaucoma Device Versus Trabeculectomy. <i>Journal of Glaucoma</i> , 2014, 23, 385-390.	1.6	31
67	Topical glaucoma therapy cost in Mexico. <i>International Ophthalmology</i> , 2014, 34, 241-249.	1.4	5
68	Fixed-combination treatments for intraocular hypertension in Chinese patients – focus on bimatoprost-timolol. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2617.	4.3	4
69	Comparison of United States and Canadian Glaucoma Medication Costs and Price Change from 2006 to 2013. <i>Journal of Ophthalmology</i> , 2015, 2015, 1-8.	1.3	16
70	Economics of Glaucoma Care. , 2015, , 20-29.		0
71	A Study of the Association Between Patterns of Eye Drop Prescription and Medication Usage in Glaucoma Subjects. <i>Journal of Glaucoma</i> , 2015, 24, 202-206.	1.6	7
72	A comparison of measures used to describe adherence to glaucoma medication in a randomised controlled trial. <i>Clinical Trials</i> , 2015, 12, 608-617.	1.6	20
73	Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for Glaucoma. <i>American Journal of Ophthalmology</i> , 2016, 163, 70-74.e1.	3.3	17
74	Health-economic evaluation of fluocinolone acetonide 190â%Âµg implant in people with diabetic macular edema. <i>Current Medical Research and Opinion</i> , 2017, 33, 45-52.	1.9	8
75	Cost comparison of commonly used postoperative topical ophthalmic antibiotics. <i>Journal of Cataract and Refractive Surgery</i> , 2017, 43, 1322-1327.	1.5	9

#	ARTICLE	IF	CITATIONS
76	The Effect of an Educational Intervention on Adherence to Intraocular Pressure-Lowering Medications in a Large Cohort of Older Adults with Glaucoma. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 1284-1294.	0.9	14
77	A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery. <i>JAMA Ophthalmology</i> , 2018, 136, 1271.	2.5	22
78	Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 591-604.	1.9	25
79	North American cost analysis of brand name versus generic drugs for the treatment of glaucoma. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 789-798.	1.9	6
80	Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the glaucoma initial treatment study randomised clinical trial. <i>British Journal of Ophthalmology</i> , 2020, 104, 813-821.	3.9	22
81	Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China. <i>Journal of Ophthalmology</i> , 2020, 2020, 1-5.	1.3	5
82	Primary Open-Angle Glaucoma Preferred Practice Pattern®. <i>Ophthalmology</i> , 2021, 128, P71-P150.	5.2	144
83	Cost Analysis and Rational Use of Anti-Glaucoma Therapy in a Tertiary Hospital in Ghana. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 619-627.	1.9	1
84	Difference in patterns of retinal ganglion cell damage between primary open-angle glaucoma and non-arteritic anterior ischaemic optic neuropathy. <i>PLoS ONE</i> , 2017, 12, e0187093.	2.5	13
85	Impact of Patient Access to Internet Health Records on Glaucoma Medication: Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2014, 16, e15.	4.3	11
87	Análise do Comportamento Prescritivo de Medicamentos de Uso Contínuo: Um Survey Realizado com Oftalmologistas Brasileiros. <i>Revista De AdministraçãO Da Unimep</i> , 2013, 11, 25-50.	0.1	0
88	Volumetric and cost evaluation study of glaucoma medical therapy. <i>International Journal of Applied & Basic Medical Research</i> , 2015, 5, 96.	0.5	2
89	A Pharmacoeconomic Analysis to Determine the Relative Cost-effectiveness of Timolol 0.5%, Brinzolamide 1% and Brimonidine 0.2% Eye Drops in Treatment of Primary Open Angle Glaucoma/Ocular Hypertension. <i>International Journal of Medical and Dental Sciences</i> , 2019, 8, 1766-1774.	0.1	0
90	Considerations in glaucoma therapy: fixed combinations versus their component medications. <i>Clinical Ophthalmology</i> , 2010, 4, 1-9.	1.8	74
91	A Cross-Sectional Study on Socioeconomic Status of Glaucoma Patients and Prescription Burden of Antiglaucoma Drugs in Pakistan. <i>International Journal of Pharmacology</i> , 2022, 18, 207-214.	0.3	0
92	Psychometric Evaluation of Glaucoma Quality of Life Item Banks (GlauCAT) and Initial Assessment Using Computerized Adaptive Testing. <i>Translational Vision Science and Technology</i> , 2022, 11, 9.	2.2	2
93	Review on Cost of Anti-Glaucoma Formulation Available in India. <i>Biomedical and Pharmacology Journal</i> , 2022, 15, 1213-1225.	0.5	0
94	Genes as drugs for glaucoma: latest advances. <i>Current Opinion in Ophthalmology</i> , 2024, 35, 131-137.	2.9	0